Lantern Pharma Receives U.S. Patent Allowance for LP
Lantern Pharma (NASDAQ: LTRN) said the U.S. Patent and Trademark Office issued a Notice of Allowance for a patent covering patient selection and treatment for ovarian, primary liver, kidney and thyroid cancers using LP-184 (zirdafulven). The allowed claims relate to a three-gene biomarker signature (PTGR1, PTPN14, ASPH). Lantern cited a 45% disease control rate at or above the effective dose in Phase 1a and plans multiple Phase 1b/2 studies in 2026.
How this was made
The 30-second read
Why it matters
The USPTO Notice of Allowance adds IP momentum around the specific three-gene biomarker signature (PTGR1, PTPN14, ASPH) used for selecting and treating ovarian, primary liver, kidney, and thyroid cancer patients.
Market read
Traders may view the IP milestone as incremental positive for LP-184’s risk profile and potential partnering leverage, but it is not a clinical efficacy or regulatory approval event.
What to watch
The article does not quantify likelihood of claim scope, prosecution outcomes, or how the biomarker signature performs prospectively in later-phase studies, which are key for commercial relevance.
Background
Lantern Pharma’s LP-184 (zirdafulven) is being developed with a biomarker strategy using its RADR AI platform to identify patients likely to benefit.
Ticker impact
Lantern Pharma received a USPTO Notice of Allowance for LP-184, with claims tied to a three-gene biomarker signature for patient selection.
Near-term upside bias as investors price improved IP defensibility; magnitude likely moderate without new clinical efficacy data.
The article is a primary regulatory/IP milestone (Notice of Allowance) and includes specific biomarker claim details, but provides no new Phase 1a efficacy update beyond previously stated figures.
Market effects
Reinforces the precision-oncology trend of biomarker-defined patient selection and AI-assisted discovery as a defensible development path.
No direct regional market linkage beyond general US biotech IP news.
US patent allowance can improve global licensing/partnering prospects for LP-184.
Counterpoint
A Notice of Allowance is not a granted patent, and investors may overreact versus the probability/timing of final issuance and enforceability.
Key entities
- companyLantern Pharma
NASDAQ-listed biotech developing LP-184 and other oncology assets, using AI for biomarker discovery.
- drug_candidateLP-184 (zirdafulven)
Investigational therapy whose patent claims cover biomarker-based patient selection and treatment methods.
- technology_platformRADR AI platform
AI system cited as instrumental in identifying the biomarker signature for LP-184.
- regulatorUSPTO
Issued the Notice of Allowance for the patent application covering LP-184 methods and biomarker signature claims.
